Clinical Trial Update: Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer

View source ↗

Summary

This completed trial compares changes in tumor burden using 68Ga-PSMA-11 PET/CT versus 177Lu-PSMA SPECT/CT in metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 68Ga-PSMA-11 (Gallium-68 labeled PSMA-11 radiopharmaceutical)
• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Central Hospital, Nancy, France | Conditions: Prostate Cancer Metastatic | Status: COMPLETED